These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 7793820)

  • 1. Adjuvant chemotherapy for colorectal cancer.
    Rayter Z; Leicester RJ; Mansi JL
    Ann R Coll Surg Engl; 1995 Mar; 77(2):81-4. PubMed ID: 7793820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic overview of chemotherapy effects in colorectal cancer.
    Ragnhammar P; Hafström L; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer.
    Focan C; Bury J; Beauduin M; Herman ML; Vindevoghel A; Lecomte M; Brohée D; Canon JL; Focan-Henrard D;
    Anticancer Res; 2000; 20(6C):4665-72. PubMed ID: 11205198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [What's new in adjuvant therapy of colorectal cancers?].
    Louvet C
    Ann Chir; 1998; 52(6):487-90. PubMed ID: 9752495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indication and efficacy of adjuvant chemotherapy with oral fluoropyrimidines for dukes' B colorectal cancer.
    Yoshimatsu K; Umehara A; Ishibashi K; Yokomizo H; Yoshida K; Fujimoto T; Watanabe K; Ogawa K
    Anticancer Res; 2006; 26(4B):3089-93. PubMed ID: 16886639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
    Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ki-ras mutation type and the survival benefit from adjuvant chemotherapy in Dukes' C colorectal cancer.
    Gnanasampanthan G; Elsaleh H; McCaul K; Iacopetta B
    J Pathol; 2001 Dec; 195(5):543-8. PubMed ID: 11745689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of adjuvant chemotherapy on patients with stage III colorectal cancer: l-LV/5FU chemotherapy as a modified RPMI regimen is an independent prognostic factor for survival.
    Hotta T; Takifuji K; Arii K; Yokoyama S; Matsuda K; Higashiguchi T; Tominaga T; Oku Y; Yamaue H
    Anticancer Res; 2006; 26(2B):1425-32. PubMed ID: 16619554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Meta-analysis of postoperative adjuvant chemotherapy for Dukes' B colorectal carcinoma].
    Wan XB; Pan ZZ; Chen G; Li LR; Wan DS
    Ai Zheng; 2005 May; 24(5):600-4. PubMed ID: 15890106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deleted in colorectal cancer protein expression as a possible predictor of response to adjuvant chemotherapy in colorectal cancer patients.
    Gal R; Sadikov E; Sulkes J; Klein B; Koren R
    Dis Colon Rectum; 2004 Jul; 47(7):1216-24. PubMed ID: 15148649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of 5-fluorouracil metabolic enzyme genes in Dukes' stage B and C colorectal cancer patients treated with oral 5-fluorouracil-based adjuvant chemotherapy.
    Yamada H; Iinuma H; Watanabe T
    Oncol Rep; 2008 Mar; 19(3):729-35. PubMed ID: 18288408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group.
    Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM;
    Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SMAD4 levels and response to 5-fluorouracil in colorectal cancer.
    Alhopuro P; Alazzouzi H; Sammalkorpi H; Dávalos V; Salovaara R; Hemminki A; Järvinen H; Mecklin JP; Schwartz S; Aaltonen LA; Arango D
    Clin Cancer Res; 2005 Sep; 11(17):6311-6. PubMed ID: 16144935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
    Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
    Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of 10-year survival by Japanese radical lymph node dissection in patients with Dukes' B and C colorectal cancer: a 17-year retrospective study.
    Mukai M; Ito I; Mukoyama S; Tajima T; Saito Y; Nakasaki H; Sato S; Makuuchi H
    Oncol Rep; 2003; 10(4):927-34. PubMed ID: 12792747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-operative immunoprophylaxis with interleukin-2 may improve prognosis in radical surgery for colorectal cancer stage B-C.
    Brivio F; Fumagalli L; Lissoni P; Nardone A; Nespoli L; Fattori L; Denova M; Chiarelli M; Nespoli A
    Anticancer Res; 2006; 26(1B):599-603. PubMed ID: 16739327
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group.
    Glimelius B; Dahl O; Cedermark B; Jakobsen A; Bentzen SM; Starkhammar H; Grönberg H; Hultborn R; Albertsson M; Påhlman L; Tveit KM;
    Acta Oncol; 2005; 44(8):904-12. PubMed ID: 16332600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapy of colorectal carcinoma].
    Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
    Srp Arh Celok Lek; 1998; 126(11-12):506-11. PubMed ID: 9921027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis in Duke's B colorectal carcinoma: the Jass classification revisited.
    De Quay N; Cerottini JP; Albe X; Saraga E; Givel JC; Caplin S
    Eur J Surg; 1999 Jun; 165(6):588-92. PubMed ID: 10433145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.